Objectives: Diabetes mellitus-related osteoporosis is caused by the imbalance be- 
| INTRODUC TI ON
Diabetes mellitus is a chronic, systemic disease characterized by high blood glucose levels. 1 Such glucose metabolic disorders can have detrimental effects on the skeletal system. Considerable evidence has shown that diabetes mellitus decreases bone mineral density, increases the risk of fracture and affects normal osteoblast metabolism, thereby altering normal bone regeneration and healing. [2] [3] [4] Adult stem cells can be used as seed cells in bone tissue engineering. In recent years, adipose-derived stem cells (ASCs) have been revealed as promising candidates for bone tissue engineering, as they can be induced along the osteogenic lineage in a manner similar to that of bone marrow-derived stem cells (BMSCs) both in vitro and in vivo. [5] [6] [7] [8] The potential use of ASCs for bone regeneration in diabetic patients, therefore, deserves our attention.
Advanced glycation end products (AGEs) are formed by the non-enzymatic reaction of glucose with other proteins arising from long-term hyperglycaemia. 9 Their interaction can modify and alter the function of intracellular proteins and other extracellular matrix components. 9, 10 Receptor for AGEs (RAGE) is a cell membrane-specific receptor that interacts with AGEs to affect cell function. Numerous studies have shown that the AGE-RAGE interaction can induce osteoblast apoptosis, inhibit the proliferation and migration of cells, decrease bone mass and promote osteoporosis in diabetic patients. [11] [12] [13] However, it remains unclear how AGEs induce their negative effects on stem cell osteogenic differentiation.
DNA methylation is a form of epigenetic modification that
can impact a range of cellular processes, including proliferation and differentiation, by inhibiting gene expression. [14] [15] [16] [17] Katarzyna et al 16 reported that aged-related degenerative changes in MSCs could be slowed-down by down-regulating DNA methylation levels. Previously, we showed that DNA methylation levels were higher in diabetic rats than in wild-type rats, with diabetic rats also exhibiting reduced bone mass and density. 15 DNA methylation is mediated by DNA methyltransferases (DNMT1, DNMT3a, DNMT3b), which usually modify cytosine at position 5 in CpG dinucleotides to create 5-methylcytosine (5-MC). 18, 19 Therefore, changes in the expression of 5-MC and DNA methyltransferases can be used to measure whether DNA methylation affects osteogenic differentiation of AGE-treated ASCs. Thus, exploring the epigenetic regulation of ASC osteogenic differentiation may provide insight into the mechanism of diabetes-related bone disease.
In the present study, we isolated multipotent ASCs from Sprague-Dawley rats and treated cells with AGEs while undergoing osteogenic potentiation. Moreover, we tested whether AGE-RAGE signalling inhibits the osteogenic differentiation potential by modulating DNA methylation and explored the signalling pathways involved. 
| MATERIAL S AND ME THODS

| Isolation and multipotential differentiation capacity of ASCs
| Cell proliferation analysis treatment with reagents
We used a Cell Counting Kit-8 (CCK-8) assay (Sigma-Aldrich) to assess cell proliferation after treatment with advanced glycation end- 
| Alizarin Red-S staining
Mineralized nodule formation in ASC cultures was assessed using 
| Western blot assay
Cells treated with AGEs and FPS-ZM1 were lysed for total protein using a Total Protein Extraction Kit (Keygen Biotech, China).
Protein concentration was determined using the BCA protein assay kit (Thermo Scientific, MA, USA). Proteins were separated on 10% 
| Immunofluorescence staining
| Extraction of RNA and real-time polymerase chain reaction (RT-PCR)
RT-PCR was used to measure changes in the expression of a range of markers: osteopontin (Opn) and runt-related transcription factor 2 (Runx2), DNA methyltransferases 1/3a (Dnmt1/3a), receptor of advanced glycation end products (Rage), β-catenin, glycogen synthase kinase 3-beta (Gsk-3β) and lymphoid enhancer-binding factor-1 (Lef1).
Total RNA was extracted from ASCs using the total RNA extraction kit (BioFlux, China). cDNA was synthesized from total RNA using a PrimeScript RT reagent kit with gDNA Eraser (Takara Bio, Japan).
Primer sequences are presented in Table 1 
| Statistical analysis
All experiments were repeated at least 3 times independently, and representative data are provided as the mean ± SD. P values were calculated using a one-way ANOVA with spss 17.0 software (SPSS Inc., Chicago, IL, USA). Differences were accepted as statistically significant if P < .05.
| RE SULTS
| Multipotential differentiation of ASCs
ASCs from inguinal fat were cultured and passaged up to the third generation ( Figure 1A ). Treatment with osteogenic and adipogenic media noticeably changed the morphology of ASCs, differentiating into osteogenic-like cells in osteogenic medium, as shown by the mineralized-like extracellular matrix ( Figure 1B,E) ; and adipose-like Figure 1C,F) . Similarly, ASCs grown in cartilage medium suspension for 21 days were grouped into cell aggregates and stained positively with Alcian blue, indicative of cartilage-like cells ( Figure 1D ).
Overall, these findings show the multipotentiality of isolated ASCs.
| Cell proliferation
We treated ASCs with different concentrations of AGEs (40 μg, 80 μg, 120 μg, 160 μg/mL; or BSA as a negative control) or FPS-ZM1
(10 nM, 100 nM, 1 μM, 10 μM or DMSO as a negative control) for 1, 
E, Alizarin red-S staining depicts mineralized nodules (red granules). F, Oil red-O staining shows the formation of oil droplets within the cells (bright orange granules)
4 and 7 days, and then tested for changes in cell proliferation using the CCK-8 assay. We found that AGEs inhibited ASC proliferation, whereas FPS-ZM1 was non-toxic ( Figure 2 ). To maintain cell viability above 80%, we chose 80 μg/mL AGEs and 10 μM/mL FPS-ZM1 for subsequent experiments.
| AGEs/RAGE suppress ASCs osteogenic differentiation capacity
To investigate whether AGEs inhibit the osteogenic potential of ASCs through RAGE, we treated ASCs with 80 μg/mL AGEs for 21 days and tested for changes in mineralized nodule formation and gene and protein expression of OPN, RUNX2 and RAGE; the control cells were treated with 80 μg/mL BSA. Using Alizarin red-S staining, we found that AGEs reduced the degree of mineralized nodule formation in the cultures as compared with the control group ( Figure 3A ).
OPN and RUNX2 protein levels were analysed using immunofluorescence and western blotting. We found AGEs reduced the fluorescence signals ( Figure 3B ) and band intensity on western blots ( Figure 3C ) for both proteins as compared with the control treatment in a time-dependent manner. The mRNA levels for Opn and Runx2 in the AGE group were also significantly lower than in the control group at each time point ( Figure 3D ). As for RAGE, both the mRNA and protein levels of RAGE were increased at days 1, 4 and 7 ( Figure 3E ,F).
| AGEs upregulate the DNA methylation level in ASCs
DNMT1, DNMT3a and DNMT3b are key enzymes in the DNA methylation process, and 5-MC is the product of DNA methylation. We analysed how AGE treatment would affect the expression of these markers using immunofluorescence staining, western blotting and RT-PCR. Using immunofluorescence staining, we found an increase in 5-MC, DNMT1 and DNMT3a after AGE treatment at 4 days ( Figure 4A ), but no difference in DNMT3b expression (data not shown). These increases in DNMT1 and DNMT3a were confirmed by western blotting ( Figure 4B ) and RT-PCR ( Figure 4C ) at days 1, 4 and 7.
| Inhibitor of RAGE (FPS-ZM1) rescues AGEinduced loss of osteogenic potential and modulates DNA methylation in ASCs
AGE treatment reduced the osteogenic differentiation capacity of ASCs and increased the expression of DNMT1, DNMT3a and F I G U R E 2 Cell proliferation. A-C, Cell viability was significantly inhibited by AGEs in a dose-dependent and time-dependent fashion. D-F, FPS-ZM1 inhibitor is non-toxic to cells at 10 μM. Data are presented as the mean ± SD (n = 3), *P < .05, **P < .01, ***P < .001
5-MC. Therefore, in our next experiment, we explored the relationship among AGEs, DNA methylation and the osteogenic differentiation potential of ASCs. We used a RAGE inhibitor, 10 μM/ mL FPS-ZM1 (10 μM/mL DMSO as a negative control) to test whether inhibiting AGE function could rescue ASC capacity for osteogenic differentiation. Using western blotting, we found that Immunofluorescence staining (B) and western blot (C) for RUNX2 and OPN in ASCs. GAPDH serves as an internal control. Quantitative analysis for western blotting was performed by measuring the OD. D, Runx2 and Opn mRNA levels were quantified by RT-PCR analysis (n = 3). GAPDH served as internal control. RT-PCR (E) and Western blot (F) results show an increase in the expression of RAGE in a timedependent manner. Data are the mean ± SD (n = 3), *P < .05, **P < .01, ***P < .001
FPS-ZM1 treatment led to a decrease in RAGE protein and mRNA levels ( Figures 5A,B) . After 21 days, we found that FPS-ZM1 treatment increased Alizarin red-S staining, with and without AGEs ( Figure 5C ). Similarly, Opn and Runx2 mRNA levels were increased in both the FPS-ZM1 and AGEs+FPS-ZM1 groups as compared with AGE-treated group and control group ( Figure 5D ). The results of the western blot assay were consistent with those of RT-PCR ( Figure 5E ).
To further assess the effect of DNA methylation on ASC osteogenic differentiation, we measured changes in the expression of DNMT1, DNMT3a and 5-MC in the presence and absence of FPS-ZM1. 5-MC staining was strongest in the AGE group, with FPS-ZM1 co-treatment decreasing 5-MC expression by day 4
( Figure 6A ). At day 7, FPS-ZM1 and AGE co-treatment led to a decrease in Dnmt1 and Dnmt3a mRNA levels as compared with AGE treatment alone ( Figure 6B) , with consistent findings shown with western blotting for protein levels ( Figure 6C ). Together, these results suggest that FPS-ZM1 can rescue the loss of osteogenic capacity after AGE treatment, presumably by modulating DNA methylation levels in ASCs.
| FPS-ZM1 regulates Wnt signalling pathway to ameliorate the AGE-induced loss of osteogenic capacity in ASCs
The Wnt/β-catenin signalling pathway is crucial in osteogenic differentiation. Therefore, we sought to detect changes in key players within the Wnt/β-Catenin pathway, including β-Catenin, GSK-3β and LEF1, in response to AGEs and FPS-ZM1. We show that AGE treatment decreased the expression of β-Catenin and LEF1 but increased the expression of GSK-3β at days 1, 4 and 7 as compared with the control group ( Figure 7A,C) . These changes were recovered by cotreatment with FPS-ZM1 at day 7 ( Figure 7B ,C), suggesting that
AGEs inhibit the activity of the WNT signal pathway, which can be recovered by blocking RAGE signalling.
| D ISCUSS I ON
Diabetes mellitus causes glucose metabolic dysfunction and is responsible for bone loss, changes in bone quantity and quality, and F I G U R E 4 AGEs upregulate DNA methylation in ASCs. A, Fluorescence staining, (B) western blotting and (C) RT-PCR for 5-MC (green) and DNMT 1/3a (red) at day 4. 5-MC, DNMT1 and DNMT 3a were increased following AGEs treatment. Data are the mean ± SD (n = 3), *P < .05, **P < .01, ***P < .001 impaired fracture healing. 2, 4, 20 An increase in the concentration of AGEs may contribute to this diabetes-associated loss of bone health.
Indeed, others have shown that AGEs can interfere with osteoblast differentiation and induce apoptosis in bone-forming cells in patients with diabetes. 21, 22 In our study, we showed a concentrationand time-dependent reduction in ASC viability with AGE treatment.
Therefore, we investigated how AGEs affect the osteogenic potential of ASCs and the molecular mechanisms driving these changes. [28] [29] [30] We found that normal ASC proliferation, osteogenic differentiation and mineralized nodule formation were reduced by AGEs, along with an upregulation in RAGE expression. When we blocked RAGE using FPS-ZM1, we could rescue these expression levels.
DNA methylation affects a wide range of genetic molecular changes and is often associated with bone diseases. 31, 32 As adult stem cells are 
